Aberdeen Group plc Increases Position in Edgewise Therapeutics, Inc. $EWTX
Aberdeen Group plc significantly increased its stake in Edgewise Therapeutics (NASDAQ:EWTX) by 32.6% in Q4, acquiring over 200,000 additional shares. This move brings their total holdings to 821,940 shares, representing approximately 0.78% of the company. Despite some insider selling from a director and CMO, Edgewise Therapeutics maintains a "Moderate Buy" consensus rating from analysts, with an average price target of $38.44.
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Recommendation of "Moderate Buy" by Analysts
Analysts have given Edgewise Therapeutics Inc. (NASDAQ:EWTX) a consensus "Moderate Buy" rating, with an average 12-month price target of $38.44. This comes despite recent insider selling by the CMO and a director, and the company missing its last quarterly EPS estimates. Edgewise Therapeutics is trading near its 52-week high, with a market capitalization of approximately $3.58 billion.
Edgewise Therapeutics (EWTX) Valuation After Positive Becker Muscular Dystrophy Extension Data
Edgewise Therapeutics (EWTX) is attracting attention due to positive long-term MESA extension data for sevasemten in Becker muscular dystrophy, leading to a significant rally in its share price. Despite its current high price-to-book ratio compared to the broader US Pharmaceuticals industry, the company's valuation is considered "about right" when compared to its pre-revenue biopharma peers, reflecting investor confidence in its drug pipeline. However, the company still faces clinical trial risks and ongoing net losses requiring future funding.
SG Americas Securities Boosts Stake in Edgewise Therapeutics
SG Americas Securities significantly increased its stake in Edgewise Therapeutics (NASDAQ: EWTX) by nearly 800% in the fourth quarter of the prior year, bringing its total holdings to 88,723 shares. This move suggests the institutional investor sees substantial potential in Edgewise Therapeutics, a clinical-stage biopharmaceutical company focused on rare disease treatments. The increased investment underscores the biotech firm's importance in the rare disease treatment landscape and its pipeline's future growth prospects.
SG Americas Securities LLC Buys 78,842 Shares of Edgewise Therapeutics, Inc. $EWTX
SG Americas Securities LLC significantly increased its stake in Edgewise Therapeutics, Inc. by 797.9%, now holding 88,723 shares valued at approximately $2.20 million. This move comes amidst notable insider selling by the company's CMO and director, collectively reducing insider ownership to 23.20%. Edgewise Therapeutics currently trades near its one-year high with a market cap of $3.58 billion and maintains a "Moderate Buy" consensus rating from analysts, with JPMorgan Chase & Co. recently raising its price target to $45.00.
Director at Edgewise Therapeutics (EWTX) awarded 339 new shares
Jonathan C. Fox, a director at Edgewise Therapeutics (EWTX), was granted 339 shares of Common Stock as a stock award on April 1, 2026. These shares were acquired at no cash cost and increased his direct ownership to 24,514 shares. The transaction is categorized as a compensation grant rather than an open-market purchase.
Edgewise Therapeutics stock hits 52-week high at 33.5 USD By Investing.com
Edgewise Therapeutics (EWTX) stock has reached a new 52-week high of $33.50, reflecting a 207% increase from its 52-week low and a 143.52% change over the past year. Despite appearing overvalued according to InvestingPro analysis, strong investor confidence is driven by positive long-term clinical trial data for its Becker muscular dystrophy treatment, sevasemten, and anticipated catalysts in its pipeline for EDG-7500. This has led multiple analysts to reiterate strong ratings and raise price targets for the company.
Edgewise Therapeutics stock hits 52-week high at 33.5 USD By Investing.com
Edgewise Therapeutics (EWTX) stock reached a 52-week high of $33.50, demonstrating a 143.52% increase over the last year. Despite being considered overvalued by InvestingPro analysis, the company shows strong investor confidence due to positive trial data for its muscular dystrophy treatment and anticipation of future catalysts for its cardiac sarcomere modulator. Analysts from Raymond James, Truist Securities, JPMorgan, and Evercore ISI have reiterated positive ratings and increased price targets for EWTX, highlighting its growth trajectory in the biotechnology sector.
Edgewise Therapeutics (NASDAQ:EWTX) CMO Joanne Donovan Sells 28,662 Shares
Edgewise Therapeutics CMO Joanne Donovan sold 28,662 shares of EWTX stock worth $926,069.22 on April 1st. The sale comes as the company's stock traded down 0.8% to $32.88 despite significant institutional investment increases from firms like Braidwell, Morgan Stanley, and UBS. Analysts currently have an average "Moderate Buy" consensus rating for EWTX with a target price of $38.44, even after the company missed its recent earnings estimates.
[Form 4] Edgewise Therapeutics, Inc. Insider Trading Activity
Joanne M. Donovan, Chief Medical Officer at Edgewise Therapeutics, Inc. (EWTX), reported an option exercise and related sale of company stock. On April 1, 2026, she acquired 28,662 shares by exercising stock options at $7.08 per share and subsequently sold all those shares at an average price of $32.3109 per share. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 26, 2025.
Edgewise Therapeutics Insider Sold Shares Worth $926,095, According to a Recent SEC Filing
An insider at Edgewise Therapeutics (EWTX) recently sold shares valued at $926,095, as disclosed in a recent SEC filing. The company, a biopharmaceutical firm focused on muscle diseases, is developing treatments for muscular dystrophies and cardiac conditions, including its lead candidate, sevasemten, which is in late-stage clinical trials. Edgewise Therapeutics also reported recent positive long-term data for sevasemten in Becker Muscular Dystrophy and presented at the 44th Annual J.P. Morgan Healthcare Conference earlier this year.
Edgewise Therapeutics (NASDAQ:EWTX) Sets New 52-Week High - Here's What Happened
Edgewise Therapeutics (NASDAQ:EWTX) shares hit a new 52-week high of $33.14 on Wednesday, closing at $32.22 with a market capitalization of $3.51 billion. The stock carries a "Moderate Buy" analyst rating with an average target price of $37.36, despite mixed analyst commentary including a recent upgrade to "strong-buy" from HC Wainwright and a "sell" from Wall Street Zen. Insider transactions show Director Badreddin Edris reducing his stake significantly, while institutional investors like OrbiMed and RA Capital have increased their positions.
Edgewise gives 4 new hires stock options for 72,000 shares
Edgewise Therapeutics (Nasdaq: EWTX) announced it granted 72,000 inducement stock options to four new non-executive employees on March 31, 2026, under its 2024 Inducement Equity Incentive Plan. Each option has an exercise price of $32.46, matching the closing price on the grant date, and vests 25% after one year, with the remainder vesting monthly over 48 months. These grants are intended to incentivize talent acquisition and retention, aligning with Nasdaq Listing Rule 5635(c)(4) for inducement awards.
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics announced it granted inducement stock options to four new non-executive employees on March 31, 2026. These grants, totaling 72,000 shares, are part of the company's 2024 Inducement Equity Incentive Plan, with an exercise price of $32.46 per share. The options will vest over four years, tied to continued employment, and were issued in accordance with Nasdaq Listing Rule 5635(c)(4).
Edgewise Therapeutics (EWTX) CMO sells 21,338 shares after option exercise
Edgewise Therapeutics' CMO, Joanne M. Donovan, exercised stock options to acquire 21,338 shares at $7.08 per share and subsequently sold all of them in open-market transactions for an average price of $32.1168 per share. This sale, conducted under a pre-arranged Rule 10b5-1 trading plan, resulted in a net sale of 21,338 shares valued at $685,308. After these transactions, Donovan directly holds 9,597 common shares and 153,662 stock options.
Insider Sell Alert: Joanne Donovan Sells 16,358 Shares of Edgewise Therapeutics Inc (EWTX)
Joanne Donovan, Chief Medical Officer at Edgewise Therapeutics Inc (EWTX), sold 16,358 shares of the company on March 27, 2026, reducing her holdings to 9,597 shares. This transaction is part of a larger trend where insiders have sold 16 times compared to 3 buys over the last year. On the day of the sale, EWTX shares traded at $30.98, with a market capitalization of $3.248 billion.
Edgewise Therapeutics (NASDAQ: EWTX) CMO sells 16,358 shares in open market
Edgewise Therapeutics CMO Joanne M. Donovan sold a total of 16,358 shares of common stock in open-market transactions on March 27, 2026, at an average price of $30.98 per share. These shares were acquired through the company's 2021 Employee Stock Purchase Plan from May 2022 to November 2024, with some purchased as recently as November 2025. Following these sales, Donovan directly holds 9,597 shares of EWTX common stock.
Edgewise Therapeutics CMO Donovan sells $506k in EWTX stock
Joanne M. Donovan, Chief Medical Officer of Edgewise Therapeutics (NASDAQ: EWTX), sold 16,358 shares for approximately $506,734 on March 27, 2026. This insider sale occurred while EWTX shares were near their 52-week high and, according to InvestingPro, appear overvalued. Despite this, analysts from Raymond James, Truist Securities, JPMorgan, and Evercore ISI have reiterated positive ratings and price targets, following positive long-term data from Edgewise Therapeutics' MESA study and anticipated catalysts for EDG-7500.
Edgewise Therapeutics, Inc. (EWTX) PT Increased to $45 at JPMorgan Amid Optimism on EDG-7500 Pipeline
JPMorgan increased its price target for Edgewise Therapeutics (EWTX) to $45 from $34 and maintained an Overweight rating, adding EWTX to its Analyst Focus List due to optimism surrounding upcoming pipeline catalysts, particularly EDG-7500. The firm anticipates the full 12-week data for EDG-7500 in Q2 2026 will significantly impact its outlook. Additionally, long-term results from the MESA study for sevasemten in Becker muscular dystrophy showed stable functional abilities over 3.5 years, with top-line data from the GRAND CANYON pivotal cohort expected in Q4, potentially supporting regulatory approval.
(EWTX) Movement Within Algorithmic Entry Frameworks
This article provides an algorithmic analysis of Edgewise Therapeutics Inc. (NASDAQ: EWTX), highlighting strong sentiment across all time horizons. It details several institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with specific entry zones, targets, and stop losses. The analysis also includes multi-timeframe signal analysis with support and resistance levels.
EWTX (NASDAQ) Form 144 lists 71,588 shares from options, ESPP, RSUs
Edgewise Therapeutics (EWTX) has filed a Form 144 notice, indicating planned sales of 71,588 shares of common stock. These shares originate from an exercise of stock options (50,000 shares), the Employee Stock Purchase Plan (9,623 shares), and restricted stock units (11,965 shares). Morgan Stanley Smith Barney LLC is identified as the broker, and cash is the indicated payment method for these transactions, though actual sales completion is not shown in the filing.
Edgewise Therapeutics stock reaches 52-week high at $31.86
Edgewise Therapeutics (EWTX) stock recently hit a 52-week high of $31.86, marking a 42.27% increase over the past year and 106% in six months. Despite being unprofitable, the company holds more cash than debt, with analysts setting price targets between $20 and $51. Positive long-term data from its MESA study and anticipated pipeline catalysts for EDG-7500 have led several firms to reiterate positive ratings and price targets.
EWTX SEC Filings - Edgewise Therapeutics, Inc. 10-K, 10-Q, 8-K Forms
This page provides access to Edgewise Therapeutics (EWTX) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material event reports (8-K), and insider trading forms. It highlights the company's clinical progress in muscular dystrophies and cardiac conditions, and contains summaries of recent Form 4 and 8-K filings detailing insider stock option grants and positive clinical data for sevasemten. The page also offers AI-powered summaries to help investors quickly understand key information.
A Look At Edgewise Therapeutics (EWTX) Valuation After Promising Sevasemten Becker Muscular Dystrophy Data
Edgewise Therapeutics (EWTX) recently released positive long-term data for its lead candidate sevasemten in Becker muscular dystrophy, showing functional stabilization over 3.5 years. Despite a strong prior run, recent share price momentum has cooled. The company's valuation, at a 6x Price-to-Book ratio, suggests a premium for its pipeline but a discount compared to more concentrated biotech peers, indicating a balanced market perspective on its future growth potential.
Edgewise Therapeutics team to attend 2026 American College of Cardiology annual meeting
Edgewise Therapeutics announced its participation in the 2026 American College of Cardiology Annual Scientific Sessions. The company plans to engage with healthcare professionals, academics, and innovators focused on cardiac muscle disease at booth number 2348. This involvement underscores Edgewise Therapeutics' ongoing dedication to advancing research and clinical connections within the cardiac healthcare sector.
Why Shares of Edgewise Therapeutics Outperformed the Market This Tuesday
Edgewise Therapeutics (NASDAQ: EWTX) saw its stock price climb over 2% on Tuesday after a JPMorgan analyst, Tessa Romero, raised her price target for the company from $34 to $45, maintaining an "overweight" rating. This optimistic revision was driven by Edgewise's promising drug pipeline, including EDG-7500 for hypertrophic cardiomyopathy and positive long-term results for sevasemten in Becker muscular dystrophy. The company is also developing two additional cardiovascular drugs, positioning it as a notable player in the biotech industry.
Why Edgewise Therapeutics Stock Topped the Market on Tuesday
Edgewise Therapeutics (NASDAQ: EWTX) stock rose over 2% on Tuesday after a JPMorgan analyst significantly increased her price target to $45 per share from $34. The analyst cited the company's investigational programs, particularly EDG-7500 for hypertrophic cardiomyopathy, and recent long-term data for its muscular dystrophy treatment, sevasemten, which showed stabilization of function in Becker muscular dystrophy patients. Edgewise is seen as a standout biotech with two high-potential medicines in advanced development and two more in the cardiovascular segment.
JPMorgan Chase & Co. Raises Edgewise Therapeutics (NASDAQ:EWTX) Price Target to $45.00
JPMorgan Chase & Co. has increased its price target for Edgewise Therapeutics (NASDAQ:EWTX) from $34.00 to $45.00, maintaining an "overweight" rating and suggesting a 45.65% upside. The company currently holds a "Moderate Buy" consensus rating from analysts with an average target price of $37.36, despite a recent EPS miss and a director selling a significant portion of shares. Edgewise Therapeutics, a clinical-stage biopharmaceutical company, focuses on precision medicines for rare diseases, particularly kidney disorders and neuromuscular diseases, with its lead candidate EWTX-101.
Edgewise Therapeutics' (EWTX) "Outperform" Rating Reiterated at Wedbush
Wedbush reiterated an "Outperform" rating for Edgewise Therapeutics (EWTX), setting a $32.00 price target, suggesting a potential 7.45% upside. Despite this, the company reported a quarterly EPS loss of ($0.47), missing estimates, and a director significantly reduced their holdings. Analysts generally maintain a "Moderate Buy" consensus with an average target of $36.36 for EWTX, which currently trades near $29.78 with a market capitalization of $3.19 billion.
Assessing Edgewise Therapeutics (EWTX) Valuation After Encouraging Long Term MESA Study Results
Simply Wall St assesses Edgewise Therapeutics (EWTX) valuation after the release of encouraging three-and-a-half-year data from its MESA open-label extension study of sevasemten for Becker muscular dystrophy. The article notes the company's strong price performance and analysts' price targets implying further upside, despite its current price-to-book ratio of 6.1x being above the industry average but below that of its direct peers. While positive clinical signals are reassuring, the analysis also highlights potential risks related to future MESA readouts and possible setbacks for its drug candidates.
HighVista Strategies Boosts Edgewise Therapeutics Stake
HighVista Strategies LLC has significantly increased its investment in Edgewise Therapeutics (NASDAQ: EWTX), a biopharmaceutical company focusing on rare disease treatments. The investment firm boosted its stake by 198.5% during the third quarter, signaling institutional confidence in Edgewise's pipeline and future growth prospects. This increased holding makes HighVista Strategies own approximately 0.20% of Edgewise Therapeutics' shares.
Edgewise Therapeutics, Inc. $EWTX Shares Purchased by HighVista Strategies LLC
HighVista Strategies LLC significantly increased its stake in Edgewise Therapeutics (NASDAQ:EWTX) by 198.5% in Q3, now holding 208,101 shares valued at approximately $3.38 million. This comes as other institutional investors also adjusted their holdings, while a company director recently sold a large portion of their shares. Analysts currently have a "Moderate Buy" consensus rating for EWTX, with an average target price of $36.36.
First Light Asset Management LLC Lowers Stock Holdings in Edgewise Therapeutics, Inc. $EWTX
First Light Asset Management LLC reduced its stake in Edgewise Therapeutics (NASDAQ:EWTX) by 17.4% in the third quarter, while several other institutional investors significantly increased their positions. Despite First Light's reduction, other large institutional investors demonstrated strong accumulation. An insider, Director Badreddin Edris, also sold a substantial portion of his holdings, yet analysts maintain a "Moderate Buy" consensus rating with a price target of $36.36 for the stock.
Edgewise Therapeutics Talks Phase III Becker Readout, EDG-7500 HCM Data Due in Q2 at Conference
Edgewise Therapeutics discussed upcoming clinical milestones for its neuromuscular and cardiovascular pipeline. The company anticipates a Phase III Becker muscular dystrophy readout by the end of 2026, aiming for regulatory filing based on open-label extension data showing patients remained progression-free. Additionally, data for EDG-7500 in hypertrophic cardiomyopathy (HCM) from 50-60 patients is expected in late Q2, with plans for an end-of-Phase II FDA meeting and Phase III initiation by year-end, emphasizing the drug's tolerable safety and lack of ejection fraction declines.
Edgewise Therapeutics (EWTX) Is Up 6.4% After New Long-Term Becker Data On Sevasemten Trial
Edgewise Therapeutics saw its stock rise by 6.4% after presenting positive long-term data from its sevasemten trial for Becker muscular dystrophy, showing functional stabilization and a favorable safety profile. While this strengthens the biological case for sevasemten, the company remains clinical-stage, loss-making, and faces key risks including the upcoming pivotal GRAND CANYON results. Investors are advised to consider the high valuation and lack of current revenue.
A Look At Edgewise Therapeutics (EWTX) Valuation After Encouraging Long Term Sevasemten Becker Data
Edgewise Therapeutics (EWTX) presented encouraging long-term data for sevasemten in Becker muscular dystrophy, leading to significant share price appreciation. The company trades at a 6.1x Price to Book ratio, which is higher than the US pharmaceuticals sector average but lower than its peer group. The article suggests that while the valuation reflects investor focus on the development pipeline, clinical and regulatory risks, along with ongoing net losses, should be considered.
Integral Health Asset Management LLC Raises Holdings in Edgewise Therapeutics, Inc. $EWTX
Integral Health Asset Management LLC significantly increased its stake in Edgewise Therapeutics (NASDAQ:EWTX) by 50% in the third quarter, now owning 1.5 million shares worth $24.33 million. Other institutions like OrbiMed and Braidwell also boosted their holdings, indicating broad institutional interest despite the company missing recent EPS estimates and a director selling shares. Analysts currently rate Edgewise Therapeutics as a "Moderate Buy" with an average target price of $36.36.
Edgewise Therapeutics (EWTX) Is Up 6.4% After New Long-Term Becker Data On Sevasemten Trial
Edgewise Therapeutics (EWTX) saw its stock rise by 6.4% following the presentation of new long-term data from its MESA open-label extension study of sevasemten for Becker muscular dystrophy. The data showed multi-year stabilization of patient function and a favorable safety profile. While this strengthens the clinical narrative around sevasemten, the company remains pre-revenue and loss-making, with significant reliance on pivotal trial results expected in late 2026.
A Look At Edgewise Therapeutics (EWTX) Valuation After Encouraging Long Term Sevasemten Becker Data
Edgewise Therapeutics (EWTX) has shown significant momentum with a 26.76% 90-day share price return and a 297.61% three-year total shareholder return, driven by encouraging long-term data for sevasemten in Becker muscular dystrophy. Despite trading at a 34% discount to the average analyst price target, its Price-to-Book ratio of 6.1x is higher than the broader US pharmaceuticals sector, indicating investors are largely valuing its development pipeline over current financials. The article suggests further evaluation of clinical and regulatory risks, alongside the company's net loss, is needed to assess the premium valuation.
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Edgewise Therapeutics (NASDAQ:EWTX) has received a "Moderate Buy" consensus recommendation from eleven brokerages, with an average 12-month price target of $36.36. This comes despite a recent insider sale by Director Badreddin Edris and the company missing its last quarterly EPS estimate. Edgewise Therapeutics is a clinical-stage biopharmaceutical company focusing on precision medicines for rare diseases, including kidney and neuromuscular disorders.
American Century Companies Inc. Buys 312,307 Shares of Edgewise Therapeutics, Inc. $EWTX
American Century Companies Inc. increased its stake in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) by 39.9% in the third quarter, now owning 1.03% of the company's stock valued at $17.77 million. Other institutional investors also adjusted their holdings in EWTX, while a company director sold a significant number of shares. Analysts currently rate Edgewise Therapeutics with a "Moderate Buy" and an average price target of $36.36.
Edgewise reports functional stability in Becker dystrophy trial
Edgewise Therapeutics (NASDAQ:EWTX) has announced positive long-term data from its MESA open-label extension study for sevasemten, showing stable functional performance in Becker muscular dystrophy patients over 3.5 years. This stability contrasts with the typical decline seen in natural history studies, with participants showing slight improvements rather than predicted declines. The company plans to release results from its pivotal GRAND CANYON trial in Q4 2026 and has also received positive analyst updates and price target increases following recent positive Phase 2 clinical trial results for EDG-7500 for hypertrophic cardiomyopathy.
Truist reiterates Edgewise Therapeutics stock rating on trial data
Truist Securities maintained a Buy rating and $46 price target for Edgewise Therapeutics (NASDAQ:EWTX) after the company reported positive data from its MESA Open-Label Extension trial, showing stabilization of function in participants with Becker muscular dystrophy (BMD) using sevasemten. The firm highlighted that the BMD program, for which there are no approved therapies, might be undervalued by investors, with potential for significant stock upside pending GRAND CANYON data in Q4 2026. Other analysts like Evercore ISI, Raymond James, Stifel, and Piper Sandler also provided updates, generally positive, following recent company news and upcoming trial readouts.
Truist reiterates Edgewise Therapeutics stock rating on trial data
Truist Securities reiterated a Buy rating and $46.00 price target for Edgewise Therapeutics (NASDAQ:EWTX) after the company reported positive results from its MESA Open-Label Extension trial, which showed stabilization of function in participants receiving sevasemten for Becker muscular dystrophy (BMD). The firm believes the BMD program is currently undervalued by investors and sees potential for significant upside with the upcoming GRAND CANYON data in Q4 2026, which could lead to registration. Edgewise Therapeutics stock has seen a 95% gain over the last six months and holds a strong financial position with a current ratio of 19.85.
Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up
Edgewise Therapeutics announced positive long-term data from its MESA open-label extension study of sevasemten for Becker muscular dystrophy, showing sustained functional stabilization in treated participants over 3.5 years. This stabilization contrasts sharply with the predicted functional decline seen in natural history studies of the disease. The company expects to release results from the pivotal GRAND CANYON placebo-controlled cohort in Q4 2026, aiming for the first marketing application for a Becker muscular dystrophy treatment.
Edgewise’s New EDG-7500 Study Signals Broader Cardiovascular Ambitions
Edgewise Therapeutics (EWTX) has announced a new Phase 1 clinical study for EDG-7500, an oral drug tablet aimed at muscle and cardiac biology. This early-stage study will focus on safety, tolerability, and pharmacokinetics in healthy Caucasian and Japanese adults, laying the groundwork for potential future trials in heart or muscle diseases. The expansion indicates Edgewise's strategy to broaden its cardiomuscular portfolio and potentially enhance its strategic value.
Edgewise’s New EDG-7500 Study Signals Broader Cardiovascular Ambitions
Edgewise Therapeutics (EWTX) has announced a new Phase 1 study for EDG-7500, an oral drug targeting muscle and cardiac biology. This open-label study will assess the safety, tolerability, and pharmacokinetics of single and multiple doses in healthy adult Caucasian and Japanese participants. Although the study is "not yet recruiting," it signifies Edgewise's strategic expansion into a broader cardiomuscular portfolio, potentially smoothing future revenue risks and providing a multi-asset narrative for investors.
Vanguard Group Inc. Has $77.92 Million Stake in Edgewise Therapeutics, Inc. $EWTX
Vanguard Group Inc. reduced its stake in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) by 0.8% in Q3, now holding 4,803,941 shares valued at $77.92 million. Despite mixed Wall Street sentiment, the company has an average "Moderate Buy" rating and a consensus price target of $36.36. Edgewise Therapeutics missed its quarterly EPS estimates, and a director sold a significant number of shares, though insiders still own 23.2% of the company.
Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026
Edgewise Therapeutics, a biopharmaceutical company focusing on muscle diseases, announced its leadership will present at the Leerink Global Healthcare Conference on March 11, 2026, at 1:40 p.m. ET. The presentation will be webcast live and available for replay. The company is developing novel therapeutics for muscular dystrophies and serious cardiac conditions, with several programs in various clinical trial stages.
Edgewise Therapeutics (EWTX) Is Down 6.8% After Wider 2025 Losses And New BMD Data Plans – Has The Bull Case Changed?
Edgewise Therapeutics reported wider net losses for Q4 and full-year 2025, reaching US$50.22 million and US$167.8 million respectively. Despite these losses, the company's investment narrative hinges on the success of its sevasemten program for Becker and Duchenne muscular dystrophy, with new data presentations anticipated at the MDA conference. While an estimated fair value from the Simply Wall St Community is around US$40 per share, the company still faces significant clinical and funding risks.
